55
Participants
Start Date
February 6, 2023
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2029
Avutometinib (VS-6766) + defactinib
"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
RECRUITING
AdventHealth, Orlando
RECRUITING
Louisiana State University Medical Center New Orleans, New Orleans
RECRUITING
Stephenson Cancer Center, Oklahoma City
RECRUITING
University of New Mexico Comprehensive Cancer Center, Albuquerque
Verastem, Inc.
INDUSTRY
University of Oklahoma
OTHER